stockrow
Friday 6 November 2026
Export KYMR’s income statement to Excel — free account
Kymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
- Revenue
- +466.4%
- EPS
- −40.3%
- Free cash flow
- −186.6%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
132.01
3.89
+3.04%
Follow KYMR
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | 107.22 | 157.81 | 167.66 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (208.23) | (91.44) | (98.49) | |
P/B ratio |
— | 7.46 | 5.28 | 4.16 | |
Price to Tangible BV |
— | 7.46 | 5.28 | 4.16 | |
EV/Sales |
— | 100.65 | 145.19 | 146.07 | |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
— | (44.63) | (30.81) | (24.59) | |
EV/FCF |
— | (44.41) | (30.63) | (24.44) | |
Quick Ratio |
10.82 | 9.97 | 10.39 | 10.19 | |
Current Ratio |
11.13 | 10.34 | 10.81 | 10.47 | |
Net Debt/EBITDA |
6.61 | 9.09 | 7.66 | 8.65 | |
Debt/Assets |
0.03% | 0.05% | 0.07% | 0.08% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.08 | 0.04 | 0.03 | |
Operating CF/Net income |
0.59 | 0.88 | 1.28 | 0.77 | |
Capex/Depreciation |
(0.76) | 1.59 | 0.61 | 8.15 | |
Interest Coverage |
(2,374.71) | (933.42) | (1,379.57) | (1,064.08) | |
Research and Development Expense of Revenue |
0.00% | 183.82% | 285.65% | 2,919.92% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 32.50% | 59.24% | 589.86% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 29.14% | 46.58% | 503.41% | |
Graham Net Nets |
— | 0.05 | 0.07 | 0.11 | |
Graham Number |
— | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
— | (2.83%) | (4.29%) | (4.73%) | |
Free Cash Flow Yield |
— | (2.11%) | (3.00%) | (3.56%) | |
Revenue per Share |
0.00 | 0.66 | 0.35 | 0.03 | |
Operating CF per Share |
(0.78) | (0.55) | (0.91) | (0.79) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.78) | (0.56) | (0.92) | (0.79) | |
Cash per Share |
9.70 | 7.04 | 6.67 | 10.04 | |
Shareholders Equity per Share |
16.13 | 15.37 | 15.79 | 18.70 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
16.13 | 15.37 | 15.79 | 18.70 | |
Free Cash Flow |
(78.23) | (54.54) | (89.27) | (66.85) | |
Working Capital |
908.87 | 665.94 | 614.79 | 788.00 | |
Capital Expenditures |
(0.31) | (0.47) | (0.43) | (0.11) | |
Net Current Asset Value |
845.85 | 601.08 | 548.05 | 708.07 | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.04 | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 12.06 | — | — | |
Average Payables |
8.71 | 7.35 | 11.55 | 5.00 | |
Average Assets |
1,434.66 | 1,388.26 | 1,293.66 | 1,360.42 | |
Average Common Equity |
1,280.39 | 1,240.37 | 1,162.94 | 1,207.64 |
Columns are period end dates · fundamentals updated 2 Nov 2026